# National COVID Cohort Collaborative (N3C)

KDD Workshop on Applied Data Science for Healthcare 2020 Melissa Haendel, PhD

These slides: bit.ly/data-sci-2020





# This pandemic highlights urgent needs

- Algorithms (diagnosis, triage, predictive, etc.)
- Drug discovery & pharmacogenetics
- Multimodal analytics (EHR, imaging, genomics)
- Interventions that reduce disease severity
- Best practices for resource allocation
- Coordinate to maximize efficiency and reproducibility

All these things require the creation of a comprehensive clinical data set. Fast.



# Harmonizing data across clinical data models













# **Key N3C Stats**

#### 8/24/2020

**56** sites have executed data transfer agreements (DTA's)

39 sites obtained IRB approval

36 sites have both DTA executed and IRB approval (can begin data ingestion)

14 sites have DUA executed (can begin data analysis)

41 sites have met with Data Acquisition Group

.....18 sites have deposited data in the N3C Pipeline:

.....4 - OMOP

.....4 - TriNetX

.....4 - ACT


......6 - PCORI

#### 8/24/2020

882 individual members affiliated with:

- 269 organizations
- 47 states in the US
- 14 foreign countries

65 of the US institutions are clinical hubs; 105 are hubs or their affiliates.





### What data is in the N3C?

#### Community maintained computable phenotype for COVID-19

#### **DATA FOR 1 YEAR**

- Observations
- Specimens
- Visit
- Procedures
- Drugs
- Devices
- Conditions
- Measurements
- Location
- Provider



#### **INCLUSION CRITERIA**

- All ages
- Inclusion criteria start date of 1/1/2020, lookback period to 1/1/2018.

#### **Lab Confirmed Positive**

**LOINC** codes Positive result

#### **Lab Confirmed Negative**

- **LOINC** codes Negative result
- Asymptomatic negatives excluded

#### **Suspected Positive**


COVID Dx Code (other strong positive) with no lab result

#### **Possible Positive**

Two or more suggestive ICD codes

#### STATS FOR RESULTING COHORT

Sites	8
COVID+ cases	30,520
Deaths	5,267
Visits	12.3 mil
Clinical observations	19.9 mil
Medication records	50.4 mil
Persons	341,765



as of: 7/28/20




Collaborative
Analytics N3C Secure
Data Enclave



Justin
Guinney
Sage
Bionetworks



**Joel Saltz** Stony Brook



Secure, reproducible, transparent, versioned, provenances, attributed, and shareable analytics on patient-level EHR data



# COVID-19 Collaborative Analytical Tack Teams

Collaborative Control Collaborative				
Clinical topic	Analytical questions			
	How to predict which patients will develop AKI? Relationship between AKI, invasive ventilation, and mortality. How to predict when AKI will progress to CKD? How do outcomes correlate with dialysis timing? Oxygenation? ACEI vs. ARBs vs. ARNI differentiation?			
Critical Care	How to best prioritize limited resources? What predictors help define which patients will fare best with any given intervention?			
	What is the association between HbA1c at baseline and COVID outcomes for patients with diabetes? Are outcomes equivalent among patients with type 2 diabetes and COVID-19 using different anti-hyperglycemic medications? Relationship between COVID correlated diabetes development/exacerbation and outcome and treatment response.			
lmaging	Integrative analysis of image and clinical data to predict outcome and treatment response.			

#### How effective is convalescent plasma? What are the predictors of effectiveness? Immunosupressed/ compromised What germ line mutations predispose cancer patients to severe COVID outcomes? Oncology What endophenotypes exist for MIS-C patients? What are the consequences of childhood COVID infection? Can we build a classifier **Pediatrics** to predict MIS-C?

Determine birth outcomes across COVID-19 severity, intervention, and vaginal versus c-section deliveries; postpartum morbidity and complications in positive cases. Social Determinants of Is there a racial disparity to access in testing? What is the transmission intensity among populations by race/ethnicity, rural/urban,

Pregnancy

Health (SDoH) income, etc? Are there differences in therapy response? Short/long term Assess longer term conditions, complications, and health care utilization; do these patients have readmissions? What are their

outcomes? Are there subsets of patients with COVID-19 that are are likely to develop hypercoagulability? Risk factors for hypercoagulability? Hypercoagulability

Does therapeutic enoxaparin or LMWH improve overall outcomes in patients with COVID-19?


Complications




# Example tool deployment: COVID Knowledge Graph



**Justin Reese** Lawrence Berkeley Lab




SARS-CoV-2 protein	human protein 1	human protein 2	drug
nsp8	HLA-A	C5	eculizumab
S protein	CCNB1	BCL2	ribavirin
S protein	CCNB1	BCL2	vincristine






# N3C Provenance, Transparency, Attribution, & Rapid Sharing



Artifacts are associated with ORCiDs using the Contributor Attribution Model (CAM) cd2h.org/attribution

Provenance graph showing linkages between results, code, and source data allowing for full end-to-end reproducibility



[RP-4A9E27] DI&H - Data Quality

Researchers, projects, and artifacts are all linked together with full ontology in the enclave


0 E E ... Y

PRO JECT UIT

PP-649F27

1 result Q Type and hit Enter.

[RP-4A9E27] DI&H - Data Quality





# Joining the N3C Community

#### These slides: bit.ly/data-sci-2020



1) Data Partnership & Governance



2) Phenotype & Data Acquisition



3) Data Ingest & Harmonization



4) Collaborative Analytics



5) Synthetic Clinical Data

#### **ENGAGE:**

NCATS N3C website ncats.nih.gov/n3c

CD2H N3C website covid.cd2h.org

Onboarding to N3C cd2h.org/onboard

Manuscript doi/10.1093/jamia/ocaa196/5893482

#### Get data access:

- Institutions execute their DUAs (OSU already has one!)
- Users register with N3C
- Projects submit DURs to DAC for approval (assessment of appropriate data level only, no scientific criteria)





